A new analysis of the STEP trials carried out by semaglutide manufacturer Novo Nordisk has analyzed various trials to show the safety and efficacy of the obesity drug semaglutide in older adults (over 65 years), and found similar efficacy and safety as in the general trial populations. The study is by Prof Luca Busetto from the University of Padova in Italy and colleagues, including those from Novo Nordisk.
This article was originally published on MedicalXpress.com
Whether you jog to keep fit or compete in marathons, the physically demanding sport of running can deplete the body of essential nutrients. During a race like a half-marathon, a runner’s metabolism — or ability […]
Almost half of all Canadians regularly take at least one nutritional supplement such as vitamins, minerals, fibre supplements, antacids and fish oils. Many of these individuals are healthy and hoping to improve general well-being or prevent chronic […]
What Are Boundaries? As the word portrays, boundaries in a relationship help each person establish expectations with their partner. Boundaries can help you communicate what you are comfortable with and what you are willing to […]
© 2025 SimplyWell.ca